The frequency of undesirable effects is as follows:
Often (> 1/100, <1/10); Infrequently (> 1/1000, <1/100); Rarely (> 1/10000, <1/1000); Very rarely (<1/10000), including individual messages.
Neoplasms:
Very rarely: a pituitary tumor.
Unspecified frequency: degeneration of fibromatous nodes in women with uterine fibroids.
From the immune system:
Infrequent: hypersensitivity reactions.
Rarely: anaphylactic reactions.
From the endocrine system:
Very rarely: hemorrhage in the pituitary gland.
Metabolic disorders:
Often: impaired glucose tolerance. Men who received GnRH agonists experienced a decrease in glucose tolerance. Decreased glucose tolerance was manifested by the development of diabetes mellitus or a worsening of control over the concentration of glucose in the blood in patients with diabetes mellitus in the anamnesis.
Infrequent: hypercalcemia (in women).
From the nervous system and mental sphere:
Very often: a decrease in libido, associated with the pharmacological effect of the drug and, in rare cases, leading to its abolition.
Often: mood changes (in women), depression (in women), mood swings (in men), paresthesia, spinal cord compression (in men), headache (in women).
Very rarely: a psychotic disorder.
From the cardiovascular system:
Very often: "tides" associated with pharmacological action of the drug and, in rare cases, leading to its cancellation.
Often: myocardial infarction (in men); heart failure (in men), the risk of which increases with the simultaneous use of antiandrogenic drugs.Changes in blood pressure, manifested by a decrease in blood pressure or increased blood pressure. These changes are usually transient, and are resolved either during the treatment with Zoladex®, or after its discontinuation. In rare cases, these changes required medical intervention, including the abolition of Zoladex®.
From the skin and subcutaneous tissue:
Very often: increased sweating, associated with the pharmacological action of the drug and, in rare cases, leading to its cancellation; acne (in women), in most cases occurs within 1 month after the start of therapy with Zoladex®.
Often: alopecia (in women), as a rule, is slightly expressed, including in young patients with benign neoplasms; The rash, mostly, slightly pronounced, which was often resolved on the background of continuation of therapy.
Unspecified frequency: alopecia (in men), which manifested itself as hair loss throughout the body due to decreased concentrations of androgens.
From the musculoskeletal system:
Often: arthralgia (in women), bone pain (in men).At the beginning of treatment, prostate cancer patients can often experience a temporary increase in pain in the bones, which is treated symptomatically.
Infrequently: arthralgia (in men).
From the genitourinary system:
Very often: erectile dysfunction (in men), dryness of the vaginal mucosa and increase in the size of the mammary glands (in women).
Often: gynecomastia (in men).
Infrequent: tenderness of the mammary glands (in men), obstruction of the ureters (in men).
Rarely: ovarian cyst (in women), ovarian hyperstimulation syndrome (in women, when combined with gonadotropins).
Unspecified frequency: vaginal bleeding (in women).
Other:
Very often: reaction at the injection site (in women).
Often: reaction at the injection site (in men); a temporary increase in the symptoms of the disease in patients with breast cancer at the beginning of therapy.
Laboratory research:
Often: decrease in mineral density of bone tissue, increase in body weight.
Postmarketing application
Against the background of the use of Zoladex®, isolated cases of changes in blood test parameters, violations of liver function, pulmonary embolism and interstitial pneumonia have been noted.